Article

Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease

Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Gut (Impact Factor: 13.32). 03/2008; 57(2):205-10. DOI: 10.1136/gut.2007.128231
Source: PubMed

ABSTRACT Clostridium difficile is an important cause of diarrhoea in hospitalised patients. An increasing number of cases of C difficile colitis occur in patients with inflammatory bowel disease (IBD)-Crohn's disease (CD), ulcerative colitis (UC).
To estimate the potential excess morbidity and mortality associated with C difficile in hospitalised patients with IBD.
Data from the Nationwide Inpatient Sample (2003) were analysed and outcomes were examined of patients hospitalised with both C difficile colitis and IBD compared with those hospitalised for either condition alone. The primary outcome was in-hospital mortality. A subgroup analysis was also performed comparing outcomes of C difficile infection in patients with CD and UC.
2804 discharges were diagnosed as having both C difficile and IBD, 44,400 as having C difficile alone, and 77,366 as having IBD alone. On multivariate analysis, patients in the C difficile-IBD group had a four times greater mortality than patients admitted to hospital for IBD alone (aOR = 4.7, 95% CI 2.9 to 7.9) or C difficile alone (aOR = 2.2, 95% CI 1.4 to 3.4), and stayed in the hospital for three days longer (95% CI 2.3 to 3.7 days). Significantly higher mortality, endoscopy and surgery rates were found in patients with UC compared with CD (p<0.05), but no significant difference in length of stay or median hospital charge between the two groups was seen.
C difficile colitis is associated with a significant healthcare burden in hospitalised patients with IBD and carries a higher mortality than in patients with C difficile without underlying IBD.

0 Bookmarks
 · 
115 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute severe steroid-refractory ulcerative colitis (ASUC) provides challenges for physicians and surgeons who manage these patients. When a patient is diagnosed with ASUC, they should be admitted for inpatient management including intravenous corticosteroids, venous thromboembolism prophylaxis, oral or enteral feeding if tolerated, and exclusion of infection including Clostridium difficile. Failure to improve by day 3 of corticosteroids requires escalation to medical rescue therapies such as infliximab or cyclosporine, or surgical management with colectomy. This chapter will review management of ASUC with a focus on the medical rescue options available.
    Current Treatment Options in Gastroenterology 01/2015; 13(1). DOI:10.1007/s11938-014-0036-5
  • World Journal of Gastroenterology 01/2010; 16(39):4892. DOI:10.3748/wjg.v16.i39.4892 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the effect of Clostridium difficile (C. difficile) infection in an interleukin 10-deficient (IL-10(-/-)) mouse model of inflammatory bowel disease. Bone marrow-derived dendritic cells isolated from wild type (WT) and IL-10(-/-)mice were stimulated for 4 h with C. difficile toxin A (200 μg/mL), and gene expression of interferon (IFN)-γ, IL-12 and IL-23 was determined by real-time reverse transcription polymerase chain reaction. WT and IL-10(-/-) mice (n = 20 each) were exposed to an antibiotic cocktail for three days and then were injected with clindamycin (i.p.). Mice (n = 10 WT, 10 IL-10(-/-)) were then challenged with oral administration of C. difficile (1 × 10(5) colony forming units of strain VPI 10463). Animals were monitored daily for 7 d for signs of colitis. Colonic tissue samples were evaluated for cytokine gene expression and histopathologic analysis. C. difficile toxin A treatment induced IFN-γ gene expression to a level that was significantly higher in BDMCs from IL-10(-/-) compared to those from WT mice (P < 0.05). However, expression of IL-12 and IL-23 was not different among the groups. Following C. difficile administration, mice developed diarrhea and lost weight within 2-3 d. Weight loss was significantly greater in IL-10(-/-) compared to WT mice (P < 0.05). C. difficile infection induced histopathologic features typical of colitis in both IL-10(-/-) and WT mice. The histopathologic severity score was significantly higher in the IL-10(-/-) than in WT mice (mean ± standard error; 5.50 ± 0.53 vs 2.44 ± 0.46; P < 0.05). This was accompanied by a significantly greater increase in IFN-γ gene expression in colonic tissues from IL-10(-/-) than from WT mice challenged with C. difficile (P < 0.05). These results indicate that colitis is more severe after C. difficile infection in IL-10(-/-)mice, and that IFN-γ expression is involved in this process.